Vnitr Lek 2014, 60(11):970-976

LDL-apheresis in the treatment familial hypercholesterolemia

Vladimír Bláha1,*, Milan Bláha2, Miriam Lánská2, Eduard Havel1, Pavel Vyroubal1, Zdeněk Zadák1, Pavel Žák2, Luboš Sobotka1
1 III. interní gerontometabolická klinika LF UK a FN Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc.
2 IV. interní hematologická klinika LF UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph.D.

LDL-apheresis is an extracorporeal elimination technique, which specifically removes LDL-cholesterol from the circulation. There are six methods for the selective LDL-cholesterol removal these days. The main indications for LDL-apheresis are the diagnosis of homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia which is refractory the standard care and intolerance of routine care, and also patients with lipoprotein(a) increase resistant to the farmacotherapy. There is still debate which LDL-cholesterolemia is indication for LDL-apheresis therapy, and the recommendation differs among various countries. Despite large randomized trials are missing, there are several good quality studies to conclude, that the beneficial cardiovascular effects of LDL-apheresis in severe hypercholesterolemia are important and beneficial

Keywords: atherosclerosis; cardiovascular disease; hypercholesterolemia; hypolipidemic therapy; LDL-apheresis

Received: September 29, 2014; Accepted: October 15, 2014; Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, et al.. LDL-apheresis in the treatment familial hypercholesterolemia. Vnitr Lek. 2014;60(11):970-976.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Al-Shaikh AM, Abdullah MH, Barclay A et al. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia. Cardiol Young 2002; 12(2): 105-112. Go to original source... Go to PubMed...
    2. Beigel R, Beigel Y. Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature. J Clin Apher 2009; 24(6): 219-224. Go to original source... Go to PubMed...
    3. Benlian P. Genes of lipoprotein metabolism. In: Genetics of dyslipidemia. Kluwer Academic Publishers: London 2001. ISBN 0-7923-7362-6. 41-181. Go to original source...
    4. Bláha M, Lánská M, Bláha V. Pregnancy in homozygous familial hypercholesterolemia - importance of LDL-apheresis. Atherosclerosis Suppl. Přijato do tisku 2014. Go to original source...
    5. Bláha M, Rencová E, Malý R et al. Léčba hemorheoferézou (současný stav a vlastní zkušenosti). Aktuality z nefrologie 2008; 14(3): 118-124.
    6. Bláha M, Zadák Z, Havel E et al. Léčba těžké hyperlipoproteinémie LDL-aferézou. Transfuze dnes 1997; 19: 9-10.
    7. Borberg H. The lower the better: target values after LDL-Apheresis and semi-selective LDL-elimination therapies. Transfus Apher Sci 2013; 48(2): 203-206. Go to original source... Go to PubMed...
    8. Borberg H. 26 years of LDL-apheresis: a review of experience. Transfus Apher Sci 2009; 41(1): 49-59. Go to original source... Go to PubMed...
    9. Cuchel M, Bruckert E, Ginsberg HN et al. European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35(32): 2146-2157. Go to original source... Go to PubMed...
    10. Dann EJ, Shamir R, Mashiach T et al. Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis. Transfus Apher Sci 2013; 49(2): 268-277. Go to original source... Go to PubMed...
    11. Fernández-Fuertes LF, Tapia Martín M, Nieves Plá I et al. Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia. Ther Apher Dial 2010; 14(5): 484-485. Go to original source... Go to PubMed...
    12. Fischer S, Schatz U, Julius U. Current standards in diagnosis and therapy of hyperlipoproteinemia. Atheroscler Suppl 2013; 14(1): 15-18. Go to original source... Go to PubMed...
    13. Graesdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012; 6(4): 331-339. Go to original source... Go to PubMed...
    14. Harada-Shiba M, Arai H, Oikawa S et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012; 19(12): 1043-1060. Go to original source... Go to PubMed...
    15. Hudgins LC, Kleinman B, Scheuer A et al. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102(9): 1199-1204. Go to original source... Go to PubMed...
    16. Julius U, Taseva K, Fischer S et al. Current situation of lipoprotein apheresis in Saxony. Atheroscler Suppl 2013; 14(1): 51-55. Go to original source... Go to PubMed...
    17. Kalinová M, Zadák Z, Bláha M. Léčba hyperlipoproteinémií kontinuálními plazmaferézami. Lék Zprávy (Hradec Králové) 1981; 26: 135-142.
    18. Kardaş F, Cetin A, Solmaz M et al. Successful treatment of homozygous familial hypercholesterolemia using cascade filtration plasmapheresis. Turk J Haematol 2012; 29(4): 334-341. Go to original source...
    19. Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler Suppl 2009; 10(5): 21-26. Go to original source... Go to PubMed...
    20. Klingel R, Fassbender C, Fassbender T et al. Rheopheresis: rheologic, functional, and structural aspects. Ther Apher 2000; 4(5): 348-357. Go to original source... Go to PubMed...
    21. Lánská M, Bláha M, Žák P. Extrakorporální eliminace cholesterolu u familiární hypercholesterolémie - srovnání dvou metodik. Transfuze a hematologie dnes. Přijato do tisku 2014.
    22. Leebman J, Roeseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128(24): 2567-2576. Go to original source... Go to PubMed...
    23. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82(12): 1489-1495. Go to original source... Go to PubMed...
    24. Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial 2003; 7(4): 397-401. Go to original source... Go to PubMed...
    25. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol 2013; 24(4): 288-294. Go to original source... Go to PubMed...
    26. McGowan MP. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol - the role of LDL-apheresis. J Clin Lipidol 2013; 7(3 Suppl): S21-S26. Go to original source... Go to PubMed...
    27. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478-3490. Go to original source... Go to PubMed...
    28. Page MM, Bell DA, Hooper AJ et al. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Pract Res Clin Endocrinol Metab 2014; 28(3): 387-403. Go to original source... Go to PubMed...
    29. Palcoux JB, Atassi-Dumont M, Lefevre P et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008; 12(3): 195-201. Go to original source... Go to PubMed...
    30. Pták J. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis. Transfus Apher Sci 2004; 30(2): 125-129. Go to original source... Go to PubMed...
    31. Schwarz J, Winters JL, Padmanabhan A et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28(3): 145-284. Go to original source... Go to PubMed...
    32. Stefanutti C. Treatment of severe genetic dyslipidemia: where are we going? Ther Apher Dial 2013; 17(2): 122-123. Go to original source... Go to PubMed...
    33. Stefanutti C, Vivenzio A, Di Giacomo S et al. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 2009; 49(7): 1461-1470. Go to original source... Go to PubMed...
    34. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981; 2(8254): 1005-1007. Go to original source... Go to PubMed...
    35. Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208(2): 317-321. Go to original source... Go to PubMed...
    36. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br Med J (Clin Res Ed) 1985; 291(6510): 1671-1673. Go to original source... Go to PubMed...
    37. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl 2013; 14(1): 67-70. Go to original source... Go to PubMed...
    38. Watts GF, Gidding S, Wierzbicki AS et al. Integrated guidance on the care of familial hypercholesterolemia from International FH Foundation. J Clin Lipidol 2014; 8(2): 148-172. Go to original source... Go to PubMed...
    39. Winters JL. American society for apheresis guidelines on the use of apheresis in clinical practice: Practical, concise, evidence-based recommendations for the apheresis practitioner. J Clin Apher 2014; 29(4): 191-193. Go to original source... Go to PubMed...
    40. Winters JL. Low-density lipoprotein apheresis: principles and indications. Semin Dial 2012; 25(2): 145-151. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.